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A meta-analysis of the outcome of endovascular
and noninvasive therapies in the treatment of
intermittent claudication
Anna A. Ahimastos, PhD,a Elise P. Pappas, BSpExSc, GDipExPhys,b Petra G. Buttner, PhD,c
Philip J. Walker, MBBS, FRACS,d Bronwyn A. Kingwell, PhD,a and Jonathan Golledge, MChir,
FRACS,b Melbourne, Victoria; and Townsville and Brisbane, Queensland, Australia
Purpose: Intermittent claudication is a common symptom of peripheral arterial disease. Currently, there is a lack of
consensus on the most effective therapies for this problem. We conducted a meta-analysis of randomized trials assessing
the efficacy of endovascular therapy (EVT) compared with noninvasive therapies for the treatment of intermittent
claudication.
Methods: Randomized trials comparing the efficacy of EVT and noninvasive therapies, such as medical therapy (MT) and
supervised exercise (SVE) in patients with intermittent claudication were identified by a systematic search. Data were
pooled, and combined overall effect sizes (standardized differences of mean values) were calculated for a random effect
model in terms of ankle-brachial index (ABI) and treadmill walking for initial claudication distance (ICD) and maximum
walking distance (MWD). Nine eligible trials (873 participants) were included: two compared EVT and MT alone, four
compared EVT and SVE, and three trials compared EVT plus SVE vs SVE alone.
Results: Heterogeneity between studies was marked. Quantitative data analysis suggested that EVT improved outcomes
over MT alone at early follow-up evaluations. Outcomes of EVT plus SVE were better than those of SVE alone in terms
of both ABI and treadmill walking at immediate, early, and intermediate follow-up. No substantial differences in
outcomes of EVT alone compared with SVE alone were found.
Conclusion: In patients with intermittent claudication, current evidence supports improved ABI and treadmill walking
when EVT is added toMT or SVE during early and intermediate follow-up. There is no evidence that EVT alone provides
improved outcome over SVE alone. There is low confidence in these findings for a number of reasons, including the small
number of trials, the small size of these studies, the heterogeneity in study design, and the limited use of quality of life
tools in assessing outcomes. More consistent data from larger, more homogenous studies, including longer follow-up, are
required. (J Vasc Surg 2011;54:1511-21.)
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EThe estimated prevalence of peripheral arterial disease
(PAD) in people aged 70 years is between 14% and
29%.1,2 Approximately one-quarter to one-third of patients
with PAD have symptoms of intermittent claudication.3
Many patients with intermittent claudication have signifi-
cant impairment in ambulatory function that results in
functional disability and significant lifestyle limitation and
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doi:10.1016/j.jvs.2011.06.106s reflected in impaired health-related quality of life
QOL).4,5 Treatment of patients with intermittent claudi-
ation is aimed at reducing cardiovascular risk, increasing
unctional performance, and improving health-related
OL.
Despite robust data to support the efficacy of exercise
ehabilitation programs in the treatment of intermittent
laudication, they are underused because they require a
upervised setting,6 considerable motivation to achieve a
ustained benefit, and are usually not covered by public or
rivate medical insurance plans. Currently, the most com-
only used initial therapy for intermittent claudication is
ndovascular revascularization7,8 because it can provide
mmediate benefit and is readily remunerated. Data from
tudies directly comparing noninvasive therapies and endo-
ascular revascularization are limited, however, and the
alue of endovascular treatment (EVT) for intermittent
laudication is controversial.
The objective of this study was to compare the outcome
f EVTwith other less invasive treatments in themanagement
f patients with intermittent claudication. We performed a
eta-analysis, including randomized trials that compared
VT with noninvasive treatment options, including medical
herapy (MT) and supervised exercise (SVE). Outcomes were
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November 20111512 Ahimastos et alassessed in terms of ankle-brachial index (ABI) and treadmill
walking tests, namely initial claudication distance (ICD) and
maximum walking distance (MWD).
METHODS
Search strategy. This meta-analysis was performed
with a standardized written protocol (not prepublished)
that followed the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) statement guide-
lines.9 A literature search was conducted by two authors
(A.A. and E.P.) from January 13, 2010, to June 1, 2010.
Study selection. Studies selected for review included
randomized clinical trials comparing the outcome of EVT
with noninvasive treatments, which included simple moni-
toring, MT, or SVE. The PubMed database was searched
using the keywords claudication and trial, and 1212 results
were identified. The search was then limited to claudica-
tion, angioplasty, endovascular, stent, and trial, reducing
the number of reports to 160. An identical search was
conducted using the Cochrane Library (125 reports) and
Proquest (67 reports). In addition, relevant previous liter-
ature reviews were searched for eligible trials.
The publication period had to be before June 2010 for
inclusion in the meta-analysis. No limit was placed on the
language of the publication or the earliest time of publica-
tion. The titles and abstracts of the identified publications
were screened for eligibility to this meta-analysis. By using
these search strategies, we identified 15 trials as relevant for
retrieval. Analysis of the full publications identified nine
randomized trials comparing EVT and noninvasive thera-
pies (Fig). We excluded studies that did not include all our
Fig. Flow diagram illustrates the trials identified for this
minal Revascularization; EXACT, Exercise versus Angi
trials.primary outcome measures of ABI and ICD or MWD. aData extraction, validity assessment, and risk for
ias. Two authors (A.A. and E.P.) independently ex-
racted the data from the identified studies. Any discrepan-
ies were resolved with discussion until agreement was
chieved. In the event of missing or difficult to interpret
ata, the chief investigator of the study concerned was
ontacted for further information. The quality of the stud-
es was assessed independently by two authors (J.G. and
.W.) who were blinded to names, affiliations, and addresses
f the investigators and to the journals in which the trials were
ublished. Quality assessment was based on three scales:
. The 17 checklist items required in the “Methods” and
“Results” of randomized controlled trials according to the
Consolidated Standards of Reporting Trials (CONSORT)
statement;
. A scale of six criteria devised by our group10 to assess
hypothesis setting, outcome assessment, randomiza-
tion, blinding, reporting of patient numbers, and anal-
ysis, with a score of 0 to 8; and
. The previously validated scale by Jadad et al,10-12 with a
score of 0 to 5.
Agreement between the two assessors was judged using
he concordance correlation coefficient (CCC) presented
ith the 95% confidence interval (CI).13 For each scale, the
cores from the two assessors were added and ranked to
etermine the trials of high and low quality. Publication
ias was assessed graphically using funnel plots and statis-
ically using the classic fail-safe N, when appropriate.
Study characteristics and definitions. Study design,
atient characteristics, target lesion characteristics, out-
ome measures, and follow-up periods were reviewed to
a-analysis. CLEVER, Claudication: Exercise vs Endolu-
ty in Claudication Trial; RCT, randomized controlledmet
oplasssess clinical heterogeneity. Patient characteristics that
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Volume 54, Number 5 Ahimastos et al 1513were noted included age, sex, body mass index, the pres-
ence of hypertension, the presence of diabetes mellitus, and
smoking status.Most studies did not report baseline patient
characteristics such as cardiac disease, pulmonary disease,
dyslipidemia, and stroke. Lesion characteristics recorded
included the number of femoropopliteal and aortoiliac
lesions in patients in the EVT and control groups and the
type of intervention used to treat these lesions (ie, percuta-
neous transluminal angioplasty or stenting). The trial inter-
vention details recorded also included the type of MT and
the type of exercise training.
Outcome assessment. The primary outcome mea-
sures used were ABI, ICD, and MWD. We planned to
include health-related QOL as a secondary outcome mea-
sure. Most trials did not report health-related QOL out-
comes, and the corresponding authors were contacted for
original data but in most cases did not respond. Health-
related QOL was subsequently excluded as an outcome
measure. Times at which outcomes were reported varied
from study to study. Assessment periods were recorded as
immediate (3-6 months), early (1 year), and intermediate
follow-up (2 years).
Quantitative data synthesis. Standardized differ-
ences of mean (ie, the difference in means divided by the
average standard deviation) were used as a treatment effect
measure for the three quantitative outcome measures ABI,
ICD, and MWD at immediate, early, and intermediate
follow-up. Estimation of mean values and standard devia-
tions were derived frommedian values and ranges provided
for one study.14 Standard deviations were calculated from
standard error of the means from two studies15-17 and were
approximated from standard deviations of other studies for
Greenhalgh et al18 for ABI andMWD because they did not
provide measures of dispersion. Standard deviations of ABI
were calculated from the standard deviations of ankle pres-
sure and systolic blood pressure for the study of Gelin et
al.19 Missing data were sought from the corresponding
authors where appropriate; however, no additional data
were received. Stated reasons for this included constraints
by the institution or funding body, or inability to retrieve
and transfer data.
Combined overall effect measures were calculated for
random effect model assumptions and are presented with
95% CIs. Statistical heterogeneity was assessed using the 2
distributed Q statistic. Sensitivity analyses excluded one
study that was judged to be of lower quality vs all other
studies.16,17 Throughout the analysis, a value of 0.05 was
considered significant. Statistical analysis was conducted
using Comprehensive Meta-Analysis 2 software (Biostat,
Englewood, NJ).
RESULTS
Characteristics of included clinical trials. We iden-
tified 15 relevant clinical trials assessing the efficacy of EVT
vs noninvasive therapies, of which nine met our inclusion
criteria (873 participants, Table I) and six were excluded
(Fig). Reasons for exclusion were one trial was discontin-
ued due to persistent difficulties in recruitment,23 one trial has in progress,24 two trials were nonrandomized,25,26 one
rial did not report any data on functional capacity,27 and
ne trial had incomplete reporting of results.28 The chief
nvestigator of the latter trial was contacted for further
nformation but was unable to provide any assistance.28
Two trials reported outcomes at different intervals in
wo separate publications.15-17 Both publications from
ach trial were used to obtain data for the meta-analysis. In
he trial of Greenhalgh et al18 the separate results were
eported for patients with femoropopliteal and aortoiliac
esions, and we therefore present the results separately. In
ll trials except one,16,17 the authors reported that the EVT
nd control groups both received MT. The MT report
aried from specific drug therapy to general advice on
moking cessation and exercise (Table I).
The design of the randomized, single-center trials,
ncluding interventions, sample size, and follow-up, is re-
orted in Table I. In combining the results to summarize
utcomes, three comparisons were identified: (1) EVT
ompared with MT alone (2 trials),15,20,21 (2) EVT com-
ared with SVE (4 trials),14,16,17,19,22 and (3) EVT plus
VE compared with SVE alone (3 trials).14,18
Two trials were each considered as two separate trials due
o (1) one trial was able to provide data in more than one
omparison because three groups were studied,14 and (2) one
rial provided separate outcomes for femoropopliteal and iliac
esions.18 When the same group of investigators reported
esults for the same cohort at different follow-up periods in
arious journals, these results were treated as those of a single
tudy in our meta-analysis.15,16,17,20 Two trials reported that
here was no crossover between the control and EVT
roups.14,15 The crossover rate in the other trials ranged
etween 6.3% and 27%.16-19,21,22
Quality of included clinical trials. Agreement be-
ween the assessors of study quality was good for the Jadad
cale (CCC, 0.64; 95% CI, 0.30-0.83), CONSORT (CCC,
.71; 95%CI, 0.10-0.93), and theOliver scale (CCC, 0.75;
5% CI, 0.23-0.94). Both assessors agreed on the judg-
ent that one study was of lower quality.16,17 This judg-
ent was based on (1) outcome assessment was not
linded, (2) randomization process was not clearly de-
cribed, (3) lack of sample size calculation, and (4) no
ONSORT chart and no reference to withdrawals and
ropouts. This study was published in the early and mid-
990s, before uniform implementation of standardized
eporting guidelines, and hence, the identified issues might
e due to reporting rather than study design and conduct
ssues. However, at the intermediate and late stage of
ollow-up,16,17 additional patients had been included who
ere not part of the initial report.
Baseline characteristics of patients in included
tudies. None of the trials reported significant differences
etween the EVT and control groups for any of entry
emographic or risk factor characteristics, such as age, sex,
istory of hypertension, smoking, or diabetes mellitus.
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November 20111514 Ahimastos et alLesion characteristics of patients in the included
studies. Table II reports the sites of PAD treated and the
initial outcomes reported for the included studies. De-
tailed information on lower limb atherosclerotic disease
was only available in both intervention and control
groups from three of the nine trials (Table II). None of
the individual studies reported significant differences
between the EVT and control groups in the number of
femoropopliteal lesions or the number of aortoiliac le-
sions. Patients in one trial were separated by whether the
main atherosclerotic lesion, which would be treated by
EVT, was in the iliac or femoropopliteal segment.18 In
the study of Mazari et al,14 all patients had femoropop-
liteal lesions; however, the authors did not report a
specific number of lesions for the EVT and control
groups (Table III). In the study of Gelin et al,19 imaging
was not obtained in the control group (patients who
Table I. Design of included randomized trials comparing
with intermittent claudication
Study Interv
EVT vs MT alone
Whyman (1996, 1997)15,20 EVT M
Nylaende (2007)21 EVT M
EVT vs SVE
Creasy/Perkins (1990, 1996)16,17 EVT
Gelin (2001)19 EVT M
Spronk (2009)22 EVT M
Mazari (2009)14 EVT M
Studies of EVT vs SVE
Greenhalgh (2008a) femoropopliteal trial18 EVT  SV
Greenhalgh (2008b) aortoiliac trial18 EVT  SV
Mazari (2009b)14 EVT  SV
EVT, Endovascular therapy; MT, medical therapy; SVE, supervised exercise.
aIliac occlusions were treated with primary stenting and iliac stenoses were se
did not report the exact number of patients that received stents.underwent SVE); therefore, no comment is made on (heir lesion characteristics. In the latter study, the EVT
roup underwent angioplasty or surgical intervention
Table I). Only 17 of 61 patients underwent angioplasty,
hereas 44 underwent surgical intervention. Thus, this
roup was not very representative of EVT.
Initial outcomes and complications. Most of the
tudies reported immediate technical success in both types
f lesions (occlusions and stenoses) treated. The failure rate
fter EVT was 0% to 25% (Table II). Two of the four
echnical failures reported in the EVT group in the trial of
pronk et al22 underwent surgical treatment. Minor com-
lications after angioplasty, including groin hematomas
nd sensory deficits, ranged from 8% to 21% (Table II).
one of these complications required further intervention.
he rate of major complications, such as arterial ruptures
nd dissections that required surgery, was low for all studies
vascular therapies versus other treatments for patients
Control
Sample size (No.)
Intervention Control
MT 30 32
MT 28 28
SVE 20 16
SVE MT 87 177
SVE MT 75 75
SVE MT 60 60
MT SVE MT 48 45
MT SVE MT 19 15
MT SVE MT 58 60
ely stented if the result after angioplasty seemed unsatisfactory. The authorsendo
ention
T
T
T
T
T
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Volume 54, Number 5 Ahimastos et al 1515plasty procedure or occurring during the hospital stay or
30 days were reported.
Primary outcomes. ABI, ICD, and MWD values at
baseline and follow-up for patients in the included studies
are presented in Table III. ABI values at baseline were
comparable between studies, but significant heterogeneity
was observed for baseline ICD andMWDvalues among the
individual studies. Greenhalgh et al18 reported ICD values
at follow-up as “percentage attaining 200m without clau-
dication pain,” and we were therefore unable to calculate
mean values. A more favorable hemodynamic outcome
for patients treated by EVT was reported in four of nine
trials during at least one follow-up assessment14-17,20,21
(Table III). The findings for the treadmill exercise test
outcomes were less consistent. ICD was reported to be
more favorable immediately after EVT in four of nine
Table I. Continued.
Follow-up (months)
EVT
Immediate Early Intermediate
Angioplasty alone and/or
stenting (No.)
6 24 Angioplasty (30/30);
stenting (0/30)
3 12 24 Angioplasty (28/28)a
3 12 Angioplasty (20/20);
stenting (0/20)
12 Angioplasty (17/61);
stenting (0/61); surgica
intervention (44/61)
6 12 Angioplasty (75/75);
stenting (50/75); surgic
intervention (2/75)
3 Angioplasty (60/60);
stenting (0/60)
6 12 24 Angioplasty (44/48);
stenting (0/44)
6 12 24 Angioplasty (19/19);
stenting (5/19)
3 Angioplasty (58/58);
stenting (0/60)trials reporting these treadmill outcomes within 6 donths of randomization.14-17,20,21 More favorable re-
ults at early and intermediate (1 year) follow-up after
VT was only reported in one of nine trials that reported
hese results.21 More favorable MWD results were re-
orted immediately after EVT in five of nine trials within
months of randomization.15-18,20,21 This improve-
ent in MWD after EVT was maintained at early and
ntermediate follow-up in four of nine trials.18,19,21
Results of quantitative meta-analysis. The nine
tudies were stratified into three groups for the meta-
nalysis: EVT compared with MT alone (n  2), EVT
ompared with SVE (n  4), and EVT plus SVE com-
ared with SVE alone (n  3). Results for these compar-
sons are discussed below and reported in Table IV.
nterpretation of these results must take into account the
arked heterogeneity among the studies, which was
MT SVE
Aspirin  advice on smoking and
exercise
. . .
Zyban, nutritional advice, home-
based training program, including
walking, statins, acetylsalicylic
acid, Plavix, antihypertensives
. . .
. . . Walking, cycling, step-
ups
Advice on smoking and risk factor
management
Walking
Aspirin  atherosclerotic risk factor
treatment  advice on smoking
Treadmill walking
Aspirin and/or clopidogrel, smoking
cessation advice/support, target
oriented management of
hypertension,
hypercholesterolemia and
diabetes, exercise advice
Walking up and down a
6-inch step, double
heel raise, single leg
press, cycling, knee
extension, elbow
flexion
Aspirin/clopidogrel 
atherosclerotic risk factor
treatment
Walking, stair climbing,
heel raises
Aspirin/clopidogrel 
atherosclerotic risk factor
treatment
Walking, stair climbing,
heel raises
Aspirin and/or clopidogrel, smoking
cessation advice/support, target
oriented management of
hypertension,
hypercholesterolemia and
diabetes, exercise advice
Walking up and down a
6-inch step, double
heel raise, single leg
press, cycling, knee
extension, elbow
flexionl
alemonstrated to be significant for the outcomes of ABI
f
s
f
f
t
t
f
n
a
E
q
r
D
i
E
q
M
a
c
w
d
m
Q
had co
exact
JOURNAL OF VASCULAR SURGERY
November 20111516 Ahimastos et aland ICD when comparing EVT with MT alone, MWD
when comparing EVT with SVE, and MWD when com-
paring EVT plus SVE with SVE alone at the early fol-
low-up stage (Table IV). Because standardized mean
differences were calculated, the actual values obtained
only provided a relative measure of difference rather than
absolute measure.
EVT compared with MT alone. Hemodynamic and
treadmill-walking outcomes both favored EVT at all time
points, with results being significantly better for EVT at
immediate (MWDonly), early (ABI, ICD, andMWD), and
intermediate (MWD only) follow-up assessments for at
least one outcome measure. Standardized mean differences
were 2 to 10 for ABI, 0.8 to 2.4 meters for ICD, and 0.85
to 0.92 meters for MWD (Table IV).
EVT compared with SVE.
ABIs were significantly better for patients who had
EVT at immediate and early follow-up but standardized
mean differences were small (range, 0.5-0.8). No signifi-
cant differences were found in treadmill-walking distances
between groups (Table IV).
EVT plus SVE compared with SVE alone. At the
time points for which results were available, outcomes were
significantly better for patients who had EVT plus SVE
(ABI at immediate and intermediate follow-up; ICD at
Table II. Sites of PAD at entry and initial outcomes in the
Fem-pop
EVT
EVT vs MT alone
Whyman (1996, 1997)15,20 23/30 (77)
Nylaende (2007)21c NR
EVT vs SVE
Creasy and Perkins (1990, 1996)16,17e 3/20 (15)
Gelin (2001)19 NR
Spronk (2009)22 40/75 (53)
Mazari (2009a)14f NR
EVT  SVE vs SVE alone
Greenhalgh (2008a)18 28/33 (85)
Greenhalgh (2008b)18 0/19 (0)
Mazari (2009b)14 NR
C, Control group, which involved variable therapies as outlined in Table I; E
as outlined in Table I. NR, not reported.
None of the above studies reported significant differences in regard to the s
aMinor complications include all reported groin hematomas and sensory de
bMajor complications include all reported arterial ruptures and dissections.
cAuthors report data for whole cohort: 10/56 aortoiliac lesions, 1/56 femo
dAuthors report that “A few patients had small groin haematomas”; howeve
e12/20 patients in the EVT group and 8/16 patients in the control group
fWhole cohort had femoropopliteal lesions; however, authors do not reportimmediate follow-up; MWD at early and intermediate wollow-up), except in one instance where MWD was not
ignificantly different between groups at the immediate
ollow-up assessment (Table IV). Standardized mean dif-
erences were1 to 3 for ABI, 1.4 meters for ICD, and 0.5
o 1.5 meters for MWD (Table IV).
Funnel plots for ABI, ICD, and MWD did not suggest
he existence of publication bias. According to the classic
ail-safe N, between 8 and 24 studies would be required to
egate significant results (with insignificant heterogeneity
nd two studies combined) for ABI, ICD, and MWD.
xcluding the study that was considered to be of lower
uality from the analysis16,17 did not markedly change the
esults.
ISCUSSION
EVTs are the most common interventions used for
ntermittent claudication.7,8 This meta-analysis compared
VT with other therapies, including SVE and MT. The
uantitative analysis suggested that EVT compared with
T and EVT plus SVE compared with SVE improved ABI
nd treadmill-walking distance in patients with intermittent
laudication. The standardized mean differences found
ere potentially functionally relevant at 1-meter walking
istance on a treadmill, although how such standardized
ean differences reflect on the patient’s health-related
OL life is unclear. We recently found that treadmill-
ovascular and control groups of the included studies
ns, No. (%) Aortoiliac lesions, No. (%)
C EVT C
24/32 (75) 7/30 (23) 8/32 (25)
NR NR NR
7/16 (44) 5/20 (25) 1/16 (6)
NR NR NR
45/75 (60) 71/75 (95) 68/75 (91)
NR NR NR
NR 5/33 (15) NR
NR 19/19 (100) NR
NR NR NR
roup in which endovascular therapy and additional interventions were used
type of lesions between the intervention and control groups.
liteal lesions, 45/56 combined aortoiliac and femoropopliteal lesions.
exact number is not available.
mbined aortoiliac and femoropopliteal lesions.
numbers for the EVT and control groups.end
lesio
VT, g
ite and
ficits.
ropop
r, thealking ability was related to responses in both generic and
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claudication.29 The latter suggests improved treadmill out-
comes may translate into improved QOL, although this
remains speculative. No significant differences were dem-
onstrated between treadmill outcomes for the studies com-
paring EVT and SVE.
Confidence in these findings is limited; however, for
a number of reasons, including the high heterogeneity
between studies for a number of these outcomes, the
small size and number of the studies performed, and
because three of the studies were performed 10 years
ago.15-17,20 Further clarity on the most effective thera-
pies may be obtained from the ongoing Claudication:
Exercise vs. Endoluminal Revascularization (CLEVER)
trial.24
In addition to the hemodynamic and treadmill-walking
outcomes assessed in this meta-analysis, there are a number
of other major determinants of the appropriate therapy for
an individual patient that have not generally been examined
in the current trials in a consistent way, including that a
major consideration for the therapy for intermittent clau-
dication is its effect on health-related QOL.4,5,30 The effect
of intermittent claudication in an individual patient varies
markedly, depending on many factors that might limit the
effect of a lower limb artery occlusion on lifestyle, including
comorbid disease, like cardiac failure or respiratory disease,
or musculoskeletal problems. The effect of intermittent
Table II. Continued.
Criteria for successful angioplasties
NR
Residual stenosis 30%; antegrade flow established
NR
NR 
Iliac revascularization: mean residual pressure gradient
across the treated arterial segment 10 mm Hg at
rest. Femoral revascularization: residual lumen
diameter 50%
NR
NR
NR
NRclaudication on QOL will also depend on the patient’s anterest in and requirement for walking, such as type of job
r hobbies.
Only four of the nine identified trials reportedmeasures
f health-related QOL, and the available results did not
llow meta-analysis. Nylaende et al21 reported significant
mprovement in physical and emotional functioning on the
hort Form 36-item (SF-36) questionnaire, and pain dur-
ng activity and pain severity on the Claudication Scale
CLAU-S) questionnaire in EVT patients compared with
he control group at immediate follow-up; only the
mprovement in physical functioning persisted at inter-
ediate follow-up. Spronk et al22 showed that EVT and
VE both improved the mean QOL scores of the SF-36
nd Vascular QOL questionnaires; however, the differ-
nces between the two groups were not significant.22 In
he aortoiliac trial of Greenhalgh et al,18 there was
ignificant improvement in the EVT group for the SF-36
hysical score compared with the control group, whereas
n the study by Mazari et al,14 the EVT plus SVE
ntervention had additional benefits in the psychologic
F-36 domains.
A further important consideration in the choice of
herapy by the physician and patient is the availability
nd appropriateness of SVE for the individual patient. In
any health systems, SVE programs are not publically
unded. Success of SVE requires a motivated patient who
s able and willing to attend on a regular basis and is
d angioplasties, No. (%)
Complications
Minora Majorb
0/30 (0) NR NR
0/28 (0) d 0/28 (0)
2/21 (9) 3/20 (15) 1/20 (5)
(5) patients abandoned
operatively-11/76 (15)
nts never taken to the
ative theater
NR NR
4/75 (5) 6/75 (8) 1/75 (1)
NR NR NR
11/44 (25) 5/48 (10) 1/48 (2)
2/19 (10) 4/19 (21) 0/19 (0)
NR NR NRFaile
4/76
intra
patie
operware that the results will not be instant. Uptake of SVE
e
p
n
c
o
c
c
p
t
t
p
f
a
w
h
t
e
b
a
o
JOURNAL OF VASCULAR SURGERY
November 20111518 Ahimastos et alprograms is often low, although patients frequently be-
come committed to participation once regular exercise
has commenced. Mechanisms that promote greater ac-
cess to, uptake, and sustainability of SVE programs
would appear to be an important requirement to advance
management of intermittent claudication given the fa-
vorable results.
An important consideration for patients contemplating
therapy for intermittent claudication is the incidence of
complications after EVT. In the included trials, reported
rates of minor complications, such as hematomas and sen-
sory deficits that did not require any further intervention,
varied markedly, from 8% to 21%.16-18,22 Reported rates of
major complications such as arterial ruptures and dissec-
tions that required surgery was very low for all studies
(range, 0%-5%). None of the studies reported any adverse
events after SVE.
In the current meta-analysis, walking and stair climbing
were the two most commonly reported modes of SVE.
Walking to maximum pain threshold, with sessions lasting
30 minutes, three times per week for at least 3 months, is
currently considered to be the most optimal SVE ap-
Table III. Primary outcomes at entry and follow-up for p
Study type Baseline
EVT vs MT alone
Whyman (1996 & 1997)15,20
EVT 0.74 (0.16)
C 0.71 (0.11)
Nylaende (2007)21
EVT 0.63 (0.01)
C 0.65 (0.01)
EVT vs SVE
Creasy/Perkins (1990, 1996)16,17
EVT 0.63 (0.13)
C 0.66 (0.16)
Gelin (2001)19
EVT 0.55b
C 0.56b
Spronk (2009)22
EVT 0.62 (0.18)
C 0.63 (0.17)
Mazari (2009a)14
EVT 0.70 (0.07)
C 0.65 (0.06)
EVT  SVE vs SVE alone
Greenhalgh (2008a)18
EVT 0.66 (0.14)
C 0.69 (0.12)
Greenhalgh18
EVT 0.68 (0.19)
C 0.66 (0.11)
Mazari (2009b)14
EVT 0.65 (0.07)
C 0.65 (0.06)
ABI, Ankle brachial index;C, control group which involved variable therapie
interventions were used as outlined in Table I; ICD, initial claudication dist
aP  .05.
bNo standard deviation or other measure of dispersion was provided.proach.31 However, further clarification of other effective wxercise programs could identify approaches more suited to
atients who are less motivated to walk. Improved mecha-
istic insight into how SVE improves intermittent claudi-
ation could also provide new approaches to therapy devel-
pment.
In deciding on appropriate therapy for intermittent
laudication, costs and cost-effectiveness also need to be
onsidered. In 2002, de Vries, et al32 used previously
ublished data to estimate the cost-effectiveness of available
reatments for intermittent claudication. They estimated
hat the incremental cost–effectiveness ratio was $38,000
er quality-adjusted life-year gained when EVT was per-
ormed compared with exercise alone, and $311,000 with
dditional bypass surgery, suggesting that EVT performed
henever feasible is cost-effective. However, it is not clear
ow the data used in the de Vries et al study is representa-
ive of the trial data presented in the current report. For
xample, Spronk et al33 reported there was no significant
enefit in EVT compared with SVE, and that EVT was
ssociated with higher costs. If data directly from the study
f Spronk et al were used in a cost-effectiveness model, SVE
ts randomized to EVT and control groups
ABI (mean  SD)
Immediate Early Intermediate
0.88 (0.16)a . . . 0.81 (0.16)
0.74 (0.17) . . . 0.75 (0.21)
0.92 (0.03)a 0.93 (0.02)a 0.93 (0.05)a
0.68 (0.01) 0.73 (0.02) 0.73 (0.04)
0.84 (0.19)a 0.76 (0.09)a 0.69 (0.19)
0.60 (0.03) 0.70 (0.08) 0.67 (0.2)
. . . 0.71 (0.71)a . . .
. . . 0.54 (0.85) . . .
0.76 (0.18) 0.78 (0.18) . . .
0.66 (0.17) 0.67 (0.17) . . .
0.84 (0.07)a . . . . . .
0.80 (0.07)a . . . . . .
. . . . . . 0.83 (0.12)a
. . . . . . 0.72 (0.20)
. . . . . . 0.90 (0.17)a
. . . . . . 0.74 (0.20)
0.97 (0.05)a . . . . . .
0.8 (0.07) . . . . . .
tlined in Table I; EVT, group in which endovascular therapy and additional
MWD, maximum walking distance.atien
s as ou
ance;ould be favored.
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ment for intermittent claudication are reflected in this
meta-analysis. Only a relatively small number of highly
heterogeneous studies that included small sample sizes have
currently been reported. As a result, meta-analysis of the
findings was difficult. Reporting of outcomes also varied
significantly between trials. Only one of the identified trials
reported outcomes beyond 2 years. Perkins et al17 reported
no difference in the outcome of EVT and SVE at 6 years.
Currently, the evidence for a durable functional outcome
for any of the available therapies for intermittent claudica-
tion would appear to be limited.
CONCLUSIONS
This meta-analysis suggests that where SVE programs
are available and patients are willing and able to participate
in them, outcomes as measured by treadmill walking can be
expected to be no different than EVT. The combination of
EVT plus SVE may achieve the most favorable functional
outcomes. In practice, the ideal approach for any patient
will depend on a number of factors, as outlined above, and
thus tailoring of therapy will be important to achieve the
Table III. Continued.
ICD (mean  SD) m
Baseline Immediate Early Intermediate
56 (24.8) 667 (125.9)a . . . 383 (145.2)
78 (10.8) 172 (142.0) . . . 333 (142.1)
93.5 (72.9) 316 (249.4)a 398 (244.8)a 435 (223.8)a
69.6 (54.2) 97 (99.1)a 123 (131.3)a 175 (171.8)a
91 (165.5) 225 (173.9)a 210 (63.3) . . .
77 (80.0) 130 (66.3)a 315 (198.4)a . . .
. . . . . . . . . . . .
. . . . . . . . . . . .
82 (48.0) 761 (1000) 888 (1000) . . .
104 (65.0) 1003 (1000) 1047 (1000) . . .
27.4 (10.2) 59 (13.8)a . . . . . .
33.5 (9.5) 61.2 (31.4)a . . . . . .
71 (41.0) . . . . . . . . .
63 (30.0) . . . . . . . . .
49 (38.0) . . . . . . . . .
64 (20.0) . . . . . . . . .
40.0 (10.3) 108.0 (37.8)a . . . . . .
33.5 (9.5) 61.2 (31.4)a . . . . . .optimal outcome for an individual.UTHOR CONTRIBUTIONS
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